These data suggest that, as the performance of the GAAD algorithm (without the AFP-L3 serum biomarker) was comparable with the GALAD algorithm (Cobas or μTASWAKO), the incorporation of AFP-L3 into diagnostic algorithms may not be essential for the detection of early-stage HCC. The gene discussed is AFP; the disease is hepatocellular carcinoma.